Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
Open accessThe DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the levels of interleukin (IL)-6, vascular endothelial growth factor-A, platelet-derived growth factor, placental growth factor (PLGF), and other cytokines in the aqueous fluid of patients with neovascular age-related macular degeneration who respond poorly to ranibizumab. Patients and methods: This is an observational, prospective study. Thirty-two eyes from 30 patients were included in the study: 11 patients who responded poorly to ranibizumab and were switched to aflibercept (AF group), 8 patients who received ranibizumab and photodynamic therapy (PDT group), and 13 patients who responded to ranibizumab (control group). Aqueous fluid samples were collected for analysis of cytokine levels at baseline and after 1, 2, and 3 months of treatment. The effect of treatment on cytokine levels was compared between the study groups and between different time points using a linear mixed-effect regression model. Results: In the AF group, there was an increase in vascular endothelial growth factor-C, IL-7, and angiopoeitin-2 levels ( P =0.01) and a decrease in intercellular adhesion molecule and IL-17 levels ( P =0.01) between baseline and 3 months. After adjustment for age, sex, race, and type of lesion at baseline, the PLGF level was higher ( P =0.02) and the IL-7 level was lower ( P =0.04) in the ranibizumab non-responder group than in the ranibizumab responder group. Conclusion: Switching from ranibizumab to aflibercept did not reduce intraocular levels of angiogenesis cytokines, but resulted in improvement of central subfield thickness. PLGF levels were higher in poor responders to ranibizumab. The response of lesions to medication might be related to the stage of choroidal neovascularization. Trial registration: www.ClinicalTrial.gov (NCT02218177c). Keywords: neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF non-responder, poor responder, ranibizumab and AMD
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, no approved therapy for wet AMD targets VEGF-C, a potentially important target and driver of treatment resistance. 21 – 24”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, VEGF-C concentrations are reportedly elevated in the eye following treatment with VEGF-A inhibitors, suggesting that VEGF-A suppression induces compensatory upregulation of VEGF-C. 21 , 23 , 24”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and has been shown to promote vessel permeability and vascular leakage. 23”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Introduction Wet age-related macular degeneration (AMD) is one of the leading causes of blindness in adults and its pathogenesis is characterized by choroidal neovascularization (CNV).(1,2) Ranibizumab (Lucentis; Genentech Inc.”
Global estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Gene selection and classification of microarray data using random forest
Díaz-Uriarte, R., & Alvarez de Andrés, S. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-3 · Cited by 2,929 · cited 1×
“4, R: A language and environment for statistical computing, 2016; R Foundation for Statistical Computing, Vienna, Austria), propensity score adjustment was performed using the R library twang,(30) and variable selection was performed using the R library varSelRF.(31) A P-value of 0.”
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 3×
“Aflibercept (VEGF Trap; Bayer AG, Leverkusen, Germany; Regeneron, Tarrytown, NY, USA) is a recombinant soluble VEGF receptor protein that has a high affinity for all VEGF isoforms and for PLGF. 10 The VIEW 1 and VIEW 2 studies showed non-inferiority and clinical equivalence of afliber-cept to monthly ranibizumab in th…”
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555 · cited 1×
“38 IL-7 also has a role in the enhancement of homeostatic proliferation and prolonged survival of naïve T-cells, 39 and inhibition of IL-7 is used in the treatment of patients with lymphopenia.”
McCaffrey, D. F., Ridgeway, G., & Morral, A. R. (2004) · Psychological Methods · doi:10.1037/1082-989x.9.4.403 · Cited by 1,317 · cited 2×
“…that there were three study groups, we could not use a standard approach for propensity score adjustment and instead used the propensity score adjustment method devised by McCaffrey et al. 29 This method uses boosted logistic regression to generate propensity scores across three or more groups.”
Research works printed but not linked: 2
- [28]Robert CP Monte Carlo Methods Wiley Online Library 2004
- [53]Izumi-Nagai K Nagai N Ozawa Y Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization Am J Pathol 2007 170 6 2149 2158 17525280 PMC1899441
Cited by
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
“…growth factors and pro-inflammatory mediators after anti-VEGF treatment in subpopulations of patients categorized as low- to non-responders (Pongsachareonnont et al., 2018), suggesting that there is complexity in the underlying mechanisms of inflammation, and in the identification and role…”
BackgroundTian, Y., Zhang, F., Qiu, Y., Wang, S., Li, F., Zhao, J., Pan, C., Tao, Y. K., Yu, D., & Wei, W. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00764-3 · Cited by 158
The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases
Bergen, T. V., Etienne, I., Cunningham, F., Moons, L., Schlingemann, R. O., Feyen, J. H. M., & Stitt, A. W. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.10.006 · Cited by 120
“Moreover, a very recent paper reported that aqueous PlGF levels were significantly higher in nvAMD patients who responded poorly to ranibizumab than in those who responded to the therapy (Pongsachareonnont et al., 2018).”
Balser, C., Wolf, A., Herb, M., & Langmann, T. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1419-2 · Cited by 62
“Thus, increased PGF has been identified in ocular fluids and tissue from patients with diabetic retinopathy [11, 12]), glaucoma [13], and neovascular AMD [14, 15].”
BackgroundInfluentialLitwińska, Z., Sobuś, A., Łuczkowska, K., Grabowicz, A., Mozolewska‐Piotrowska, K., Safranow, K., Kawa, M. P., Machaliński, B., & Machalińska, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00286 · Cited by 56
Metadata
- Authors
- Pongsachareonnont, P., Ying Kit Mak, M., Hurst, C., & Lam, W.-C.
- Affiliations
- Thai Red Cross Society (TH)
- Chulalongkorn University (TH)
- University of Toronto (CA)
- Corresponding author
- Lam, Wai-Ching
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 12
- Pages
- 1877-1885
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC6165786
- OpenAlex
- W2894158365
- Cited by
- 34
- References
- 67
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 1
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF therapy, aflibercept, aqueous humor, IL-7, placental growth factor, vascular endothelial growth factor, angiogenesis, photodynamic therapy, treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. https://app.cochat.ai/papers/10.2147/opth.s171636
- The paper
- Pongsachareonnont, P., Ying Kit Mak, M., Hurst, C., & Lam, W.-C. (2018). Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clinical Ophthalmology. https://doi.org/10.2147/opth.s171636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
